Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has received approval for its initial public offering and is set to list on the Sci-Tech Innovation Board, focusing on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1] Group 1: Company Overview - Beixin Life is a national high-tech enterprise specializing in the research, production, and sales of innovative medical devices for cardiovascular disease diagnosis and treatment [1] - The company is the first in China to have a product combination of intravascular functional FFR and imaging IVUS, establishing a high-performance and high-barrier system for active interventional medical devices [2] Group 2: Product Development and Innovation - As of September 30, 2025, Beixin Life has launched 11 products and has 6 products under research, covering five major categories including IVUS systems and FFR systems [2] - The core product, the IVUS system, is the first domestically developed 60MHz high-definition and high-speed IVUS product approved by the National Medical Products Administration, featuring high definition, speed, and intelligence [2] Group 3: Financial Performance - In the first half of 2025, sales revenue from FFR pressure microcatheters and IVUS catheters accounted for 82.16% of total sales, indicating the continued dominance of core products in the market [3] - Beixin Life achieved a revenue of 259 million yuan and a net profit of 45.51 million yuan in the first half of 2025, marking its first profitable period [3] Group 4: Intellectual Property and Recognition - As of June 30, 2025, Beixin Life holds 185 authorized patents domestically and internationally, including 86 invention patents and 14 PCT international patent applications [4] - The company has been recognized as a "National Specialized and New 'Little Giant' Enterprise" and has received various awards for its core products, highlighting its technological capabilities and market recognition [4] Group 5: Future Outlook - The upcoming IPO is expected to optimize the company's capital structure, reduce debt risk, and enhance its research and development capabilities [6] - Beixin Life aims to continue advancing its product development and expand the application range of existing products, solidifying its comprehensive platform for cardiovascular disease diagnosis and treatment [6]

本次上市是公司迈向新阶段的关键一步，也是北芯生命实现愿景的战略机遇。我们将以此为契机，充分 把握全球医疗器械行业向智能化、精准化加速迭代的黄金增长期，加大研发投入，继续推进在心血管智 能化精准介入领域的创新突破，并在海内外市场进一步扩大影响力。 感谢各位投资者对我们的期待，我们将始终牢记这份责任，严格遵照相关法律法规要求，确保信息披露 的准确性与透明度。未来，我们将继续与各位投资者保持紧密联系，分享公司的发展成果，在改善生命 健康的航程中，共同实现患者关爱和长期价值创造。我们期待与大家携手，创造和分享属于北芯生命更 加美好的未来，并以更加优良的业绩回报股东、回报投资者、回报社会。谢谢大家！ 深圳北芯生命科技股份有限公司首次公开发行股票并在科创板上市网上投资者交流会已接近尾声。在 此，我谨代表北芯生命，感谢大家对本次发行的热情关注和踊跃提问。也十分感谢上证路演中心、上海 证券报以及中国证券网为我们提供了良好的沟通平台和优质服务。同时，衷心感谢保荐机构中金公司及 所有中介机构为公司发行上市所做出的努力。 通过今天的网上投资者交流活动，我们对北芯生命的主营业务、经营业绩、竞争优势、募投项目、发展 战略及长期价值向大 ...